Processa Pharmaceuticals has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Market and that the matter is now closed. To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCSA:
- Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
- Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
- Processa Pharmaceuticals Announces Offering Pricing Details
- Processa Pharmaceuticals Secures $7M in Public Offering
- Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering